Accepted for/Published in: Interactive Journal of Medical Research
Date Submitted: Dec 18, 2024
Date Accepted: Feb 6, 2025
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Clinical Public Databases in Hidradenitis Suppurativa: A Viewpoint
ABSTRACT
Recent studies utilizing clinical public databases have revolutionized our understanding of Hidradenitis Suppurativa (HS), a chronic inflammatory skin condition with significant impacts on patient quality of life. These databases enable researchers to conduct large-scale studies integrating genetic, epidemiological, and clinical data, providing crucial insights into HS's genetic predispositions, comorbidities, and treatment outcomes. Findings highlight a strong genetic component and elevated risks for comorbidities like obesity, diabetes, and cardiovascular disease in HS patients. While these databases offer unprecedented research opportunities, limitations such as data representativeness and quality must be considered. Nonetheless, their benefits outweigh potential drawbacks, allowing identification of rare comorbidities, disease progression patterns, and personalized treatment strategies. Increased funding for HS research is crucial to harness these databases' full potential, develop targeted therapies, and ultimately improve patient outcomes. As HS's impact is disproportionate to current research investments, advocating for more resources and addressing database limitations will be key to advancing HS understanding and care.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.